Joel Johansson

15.7k total citations · 2 hit papers
93 papers, 6.0k citations indexed

About

Joel Johansson is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Joel Johansson has authored 93 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Molecular Biology, 36 papers in Hematology and 31 papers in Oncology. Recurrent topics in Joel Johansson's work include Cell death mechanisms and regulation (23 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Multiple Myeloma Research and Treatments (19 papers). Joel Johansson is often cited by papers focused on Cell death mechanisms and regulation (23 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Multiple Myeloma Research and Treatments (19 papers). Joel Johansson collaborates with scholars based in United States, France and Australia. Joel Johansson's co-authors include Tony Hunter, Han-kuei Huang, Andrew J. Souers, Claudio A.P. Joazeiro, Wayne J. Fairbrother, Avi Ashkenazi, Simon S. Wing, Yun‐Cai Liu, Scott A. Ness and Huaiyu Sun and has published in prestigious journals such as Science, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Joel Johansson

91 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Tyrosine Kinase Negative Regulator c-Cbl as a RING-Type, E2-Dependent Ubiquitin-Protein Ligase

1999 894 citations Joel Johansson, Tony Hunter et al. profile →
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

2017 667 citations Wayne J. Fairbrother, Joel Johansson et al. profile →

Peers

Countries citing papers authored by Joel Johansson

Since Specialization

Citations

This map shows the geographic impact of Joel Johansson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Johansson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Johansson more than expected).

Fields of papers citing papers by Joel Johansson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel Johansson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Johansson. The network helps show where Joel Johansson may publish in the future.

Co-authorship network of co-authors of Joel Johansson

This figure shows the co-authorship network connecting the top 25 collaborators of Joel Johansson. A scholar is included among the top collaborators of Joel Johansson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel Johansson. Joel Johansson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors 2023 ·Cancer Research Communications ·(unknown), Roberta Buono, Shannon M. Matulis, Vikas A. Gupta, (unknown), (unknown), (unknown), Sharmila Mallya, (unknown), (unknown), (unknown), (unknown), Vy M. Dong, Andrew W. Roberts, Joel Johansson, (unknown), (unknown), Orlando F. Bueno, Lawrence Boise, (unknown)	3
2	5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis 2020 ·Clinical Cancer Research ·Sha Jin, Dan Cojocari, Julie J. Purkal, Relja Popovic, Nari Talaty, Xiao Yu, Larry R. Solomon, Erwin R. Boghaert, Joel Johansson, Darren C. Phillips	126
3	Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness 2019 ·Molecular Cancer Therapeutics ·(unknown), Ioannis K. Zervantonakis, Laura M. Selfors, Sangeetha Palakurthi, Joyce F. Liu, Ronny Drapkin, Ursula A. Matulonis, Dorothy Hallberg, Victor E. Velculescu, Joel Johansson, Deepak Sampath, Gordon B. Mills, Joan S. Brugge	36
4	Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo 2019 ·Molecular Cancer Therapeutics ·Jason J. Zoeller, (unknown), Krishan Taneja, Benjamin Y. Tan, Neil A. O’Brien, Dennis J. Slamon, Deepak Sampath, Joel Johansson, Roderick T. Bronson, Deborah Dillon, Joan S. Brugge	25
5	The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity 2018 ·Clinical Cancer Research ·Daniel A.R. Heisey, Timothy L. Lochmann, Konstantinos V. Floros, (unknown), Krista M. Powell, Sheeba Jacob, (unknown), (unknown), Giovanna T. Stein, (unknown), Steven C. Smith, Cyril H. Benes, Joel Johansson, Andrew J. Souers, Sosipatros A. Boikos, Anthony C. Faber	22
6	Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells 2018 ·Cancer Research ·Mohamed Rahmani, (unknown), (unknown), Xin‐Yan Pei, Rebecca E. Parker, Maciej Kmieciak, Joel Johansson, Deepak Sampath, Andrea Ferreira‐Gonzalez, Steven Grant	112
7	Combination of Enasidenib and Venetoclax Shows Superior Anti-Leukemic Activity Against IDH2 Mutated AML in Patient-Derived Xenograft Models 2018 ·Blood ·Séverine Cathelin, David Sharon, (unknown), Dan Cojocari, Darren C. Phillips, Joel Johansson, Kyle J. MacBeth, Brandon Nicolay, Rohini Narayanaswamy, Sébastien Ronseaux, Guowen Liu, Steven M. Chan	23
8	Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression 2017 ·Clinical Cancer Research ·Timothy L. Lochmann, Konstantinos V. Floros, Mitra Naseri, Krista M. Powell, (unknown), Ryan J. March, Giovanna T. Stein, Patricia Greninger, (unknown), Laura R. Saunders, Scott J. Dylla, Carlotta Costa, Sosipatros A. Boikos, Joel Johansson, Andrew J. Souers, Geoffrey W. Krystal, Hisashi Harada, Cyril H. Benes, Anthony C. Faber	93
9	FLT3-ITD Activation Mediates Resistance to the BCL-2 Selective Antagonist, Venetoclax, in FLT3-ITD Mutant AML Models 2017 ·Blood ·Raghuveer Singh Mali, Elisabeth A. Lasater, Kelly Doyle, (unknown), Erwin R. Boghaert, Andrew J. Souers, Joel Johansson, Deepak Sampath	17
10	Do Statins Enhance the Anti-Cancer Activity of Venetoclax? 2017 ·Blood ·Andrew W. Roberts, Tu Xu, Jia Jia, Suresh Agarwal, Ahmed Hamed Salem, Richard J. Bellin, Lloyd T. Lam, Joel Johansson	1
11	Combinatorial Treatment of Chronic Lymphocytic Leukemia with Ibrutinib and Venetoclax Is Superior to Treatment with Single Agents in the TCL1 Mouse Model 2017 ·Blood ·(unknown), Sriram Balasubramanian, Joel Johansson, Eric Eldering, Arnon P. Kater	5
12	Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models 2016 ·Molecular Cancer Therapeutics ·Elizabeth A. Punnoose, Joel Johansson, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont, Nguyen Tan, A. Young, Michael J. Mitten, Ellen Ingalla, Walter C. Darbonne, Anatol Oleksijew, Paul Tapang, Yue Peng, Jason Oeh, Leslie Lee, Sophie Maïga, Wayne J. Fairbrother, Martine Amiot, Andrew J. Souers, Deepak Sampath	223
13	Upregulation of MAPK/MCL-1 Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML 2016 ·Blood ·Qí Zhāng, Lina Han, Ce Shi, Rongqing Pan, Man Chun John, Jeremy Ryan, Stephen E. Kurtz, Hong Mu, Vivian Ruvolo, Helen Ma, Michael Andreeff, Yingchang Mi, Jeffrey Tyner, Joel Johansson, Anthony Letai, R. Eric Davis, Marina Konopleva	5
14	MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor 2015 ·Molecular Cancer Therapeutics ·Yu Xiao, Paul Nimmer, George S. Sheppard, Milan Bruncko, Paul Hessler, Xin Lü, Lisa Roberts-Rapp, William N. Pappano, Steven W. Elmore, Andrew J. Souers, Joel Johansson, Darren C. Phillips	89
15	The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo 2011 ·Molecular Cancer Therapeutics ·Jun Chen, Sha Jin, (unknown), Xiaoli Huang, Bernard A. Liu, Michael J. Mitten, Paul Nimmer, Xiaoyu Lin, Morey L. Smith, Yu Shen, Alexander R. Shoemaker, Stephen K. Tahir, Haichao Zhang, Scott Ackler, Saul H. Rosenberg, Heather Maecker, Deepak Sampath, Joel Johansson, Chris Tse, Steven W. Elmore	119
16	Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways 2009 ·Molecular Cancer Research ·Xuesong Liu, Edward K. Han, Mark G. Anderson, Yan Shi, Dimitri Semizarov, Gang Wang, Thomas McGonigal, Lisa Roberts, Loren Lasko, Joann P. Palma, Gui‐Dong Zhu, Thomas D. Penning, Saul H. Rosenberg, Vincent L. Giranda, Yan Luo, Joel Johansson, Eric F. Johnson, Alexander R. Shoemaker	77
17	Conserved function of RNF4 family proteins in eukaryotes: targeting a ubiquitin ligase to SUMOylated proteins 2007 ·The EMBO Journal ·Huaiyu Sun, Joel Johansson, Tony Hunter	248
18	Small Interfering RNA–Mediated Polo-Like Kinase 1 Depletion Preferentially Reduces the Survival of p53-Defective, Oncogenic Transformed Cells and Inhibits Tumor Growth in Animals 2005 ·Cancer Research ·Ran Guan, Paul Tapang, Joel Johansson, Daniel Albert, Vincent L. Giranda, Yan Luo	122
19	Functional Analysis of Human Microtubule-based Motor Proteins, the Kinesins and Dyneins, in Mitosis/Cytokinesis Using RNA Interference 2005 ·Molecular Biology of the Cell ·Changjun Zhu, Jian Zhao, Marina Bibikova, Joel Johansson, Ella Bossy‐Wetzel, Jian‐Bing Fan, Robert T. Abraham, Wei Jiang	335
20	Pim-1 Kinase and p100 Cooperate to Enhance c-Myb Activity 1998 ·Molecular Cell ·Joel Johansson, Päivi J. Koskinen, (unknown), Eeva-Marja Rainio, (unknown), Ajeeta B. Dash, Robert N. Eisenman, Scott A. Ness	228

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact